Behind the Bell: Rapport Therapeutics

In this episode of Behind the Bell, Rapport Therapeutics CEO Abraham N. Ceesay speaks to the foundation of the now publicly-traded company focused on helping patients suffering from central nervous system disorders.

Transcript:

Nasdaq is not only a part of the initial listing, but they are a true partner through a company's journey, and we have felt that from day one.

Our vision at rapport is to create the leading precision neuroscience company.

We are founded, based on really, truly transformational science.

Our team is built off of scientific members that are true pioneers in this area, and we are a team that is focused on progressing that on a day-to-day basis.

Nasdaq is really the home for so many innovative companies, and listing on Nasdaq really just puts rapport in that position as well.

We are right on the cusp of initiating a very important trial in patients with treatment resistant seizure.

We really look forward to starting that trial, but most importantly, seeing the results of that trial in the coming year.